A Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients with Infantile-Onset Pompe Disease with One Year Alglucosidase Alfa Treatment
Phase of Trial: Phase IV
Latest Information Update: 19 Dec 2018
Price : $35 *
At a glance
- Drugs Alglucosidase alfa (Primary)
- Indications Glycogen storage disease type II
- Focus Therapeutic Use
- Sponsors Sanofi China Investment
- 10 Dec 2018 Status changed from not yet recruiting to recruiting.
- 31 Oct 2018 Planned initiation date changed from 6 Nov 2018 to 1 Dec 2018.
- 27 Sep 2018 New trial record